Over recent times, **Becton Dickinson (BDX)** has seen multiple shifts in the company. **Lanesha Minnix** was named General Counsel while the share price experienced volatility that urged reassessments of BDX's valuation. Notably, **Tredje AP fonden** and **Vanguard Group Inc** increased their stakes in the company, indicating potential investor confidence. Despite some insiders, like **Bertram Scott**, selling company shares, the Q1 2026 report shows a detailed financial scenario and the company's future directions after the spin-off. **Citi** upgraded BDX's price target post-update of life sciences sales and the **stock reached new 12-month high**. Some investors, like **NEOS Investment Management** and **Heartland Advisors**, purchased more BDX shares, notwithstanding warnings of expected Q1 earnings to decline. BDX beat Q1 earnings and revenue estimates, contrasting the bearish views. Announcements regarding dividend increase, Waters spin-off, and $110 million investment in U.S. Pharmaceutical supply chain for Biologic Drugs reinforced investor confidence. However, despite promising developments and Jim Cramer's favorable views, BDX's profit forecast was cut for 2026, and shares fell. Its overall impact on stock performance and valuation, especially in light of recent share price movements, will be watched keenly by investors.
Becton Dickinson and BDX News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 14:15:09 GMT -
Rating 3
- Innovation -2
- Information 6
- Rumor -3
